MIV Therapeutics Inc (fka MIVI)

[Makamai]

On July 8, 2008 Jesop & Lamont updated their BUY rating on MIV Theraputics to $20 from $2 following the reverse split. Sounds good to me, now for some cash flow from the company to get things moving. It's got a long ways to go from $1.75 to get there! See Below.

Makamai

MIVT is replaced by MIVI and the reverse split impacts the
issued and outstanding share count as indicated below:

Common Shares Pre-Split Post-Split

Authorized 480,000,000 48,000,000
Outstanding 116,113,692 11,611,370
Fully-Diluted 182,983,341 18,298,334

On June 30, 2008 MIV Therapeutics effectuated a one-for-ten
reverse stock split and ticker change as of the market open. The
split is designed to improve marketability to institutional
investorsAs a result, we are adjusting our price target from $2.00 per share to $20.00 per share and maintaining our Buy rating.
Our Investment Thesis and Stock Valuation are included herein (See the link for the complete article)
http://www.mivtherapeutics.com/_resources/articles/070808-Jesup-Lamont.pdf